Matthew J. Mitcheltree

Matthew J. Mitcheltree

Auto-generated profile, based on publicly available information

Matthew J. Mitcheltree

Harvard University

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in Nature
Verified
Journal Article
Closed access
PDF file
MMMatthew J. Mitcheltree
Matthew J. Mitcheltree
APAmarnath Pisipati
Amarnath Pisipati
ESEgor A. Syroegin
Egor A. Syroegin
KSKatherine J. Silvestre
Katherine J. Silvestre
DKDorota Klepacki
Dorota Klepacki
AMAndrew G. Myers
Andrew G. Myers

16 February 2024 in Science
Verified
Journal Article
Closed access
KWKelvin J. Y. Wu
Kelvin J. Y. Wu
BTBen I. C. Tresco
Ben I. C. Tresco
ARAntonio Ramkissoon
Antonio Ramkissoon
EAElena V. Aleksandrova
Elena V. Aleksandrova
ESEgor A. Syroegin
Egor A. Syroegin
AMAndrew G. Myers
Andrew G. Myers
We report the design conception, chemical synthesis, and microbiological evaluation of the bridged macrobicyclic antibiotic cresomycin (CRM), which overcomes evolutionarily diverse forms of antimicrobial resistance that render modern antibiotics ineffective. CRM exhibits in vitro and in vivo efficacy against both Gram-positive and Gram-negative bacteria, including multidrug-resistant strains of Staphylococcus aureus , Escherichia coli , and Pseudomonas aeruginosa . We show that CRM is highly preorganized for ribosomal binding by determining its density functional theory–calculated, solution-state, solid-state, and (wild-type) ribosome-bound structures, which all align identically within the macrobicyclic subunits. Lastly, we report two additional x-ray crystal structures of CRM in complex with bacterial ribosomes separately modified by the ribosomal RNA methylases, chloramphenicol-florfenicol resistance (Cfr) and erythromycin-resistance ribosomal RNA methylase (Erm), revealing concessive adjustments by the target and antibiotic that permit CRM to maintain binding where other antibiotics fail.

23 May 2022 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AEAndrew Ecker
Andrew Ecker
DLDorothy A. Levorse
Dorothy A. Levorse
DVDaniel A. Victor
Daniel A. Victor
MMMatthew J. Mitcheltree
Matthew J. Mitcheltree

23 March 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
MMMatthew J. Mitcheltree
Matthew J. Mitcheltree
DLDerun Li
Derun Li
AAAbdelghani Achab
Abdelghani Achab
ABAdam Beard
Adam Beard
KCKalyan Chakravarthy
Kalyan Chakravarthy
CFChristian Fischer
Christian Fischer

13 October 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DLDerun Li
Derun Li
HZHongjun Zhang
Hongjun Zhang
TLThomas W. Lyons
Thomas W. Lyons
MLMin Lu
Min Lu
AAAbdelghani Achab
Abdelghani Achab
CFChristian Fischer
Christian Fischer

30 April 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
MMMatthew J. Mitcheltree
Matthew J. Mitcheltree
JSJack W. Stevenson
Jack W. Stevenson
APAmarnath Pisipati
Amarnath Pisipati
AMAndrew G. Myers
Andrew G. Myers